Composition and method for regulating IL-2
Small molecule-based therapies address the limitations of recombinant IL-2 by modulating IL-2 expression and activity, improving treatment efficacy and safety for cancer, autoimmune diseases, and infectious diseases.
JP2026513223APending Publication Date: 2026-04-23GENETIC INTELLIGENCE INC
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025556505
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-23
- Filing Date
- 2024-03-22
- Publication Date
- 2026-04-23
AI Technical Summary
Technical Problem
Current IL-2 therapies, such as recombinant peptides, suffer from rapid systemic clearance, dose-limiting toxicity, and significant adverse effects, limiting their therapeutic efficacy in treating cancer, autoimmune diseases, and infectious diseases.
Method used
Development of small molecule-based therapies that modulate IL-2 expression and/or activity, offering increased efficacy, reduced toxicity, and improved stability through localized production and administration, avoiding issues associated with recombinant IL-2.
Benefits of technology
The small molecule therapies provide longer-lasting, higher therapeutic efficacy with reduced side effects, enhancing treatment outcomes for cancer, autoimmune diseases, and infectious diseases by modulating IL-2 levels effectively.
✦ Generated by Eureka AI based on patent content.
Abstract
This disclosure relates to modulating IL-2 expression / activity to prevent or treat diseases (cancer, autoimmune diseases, inflammatory diseases, or infections). Compounds of formula (I), as well as compositions comprising their conjugates, complexes, and pharmaceutical compositions, as well as methods of using them to modulate (e.g., increase) IL-2 expression / activity to achieve desired results (e.g., reduction in cancer cell viability, growth, proliferation, or metastasis; reduction in tumor volume; increase in survival; increase or decrease in immune cell proliferation or activation; increase or decrease in cytokine production; decrease in autoimmunity; decrease in inflammation, etc.). Related pharmaceuticals, kits, and methods of delivering such compositions are described. Compounds of formula (I) and methods for developing or manufacturing their pharmaceutical compositions are provided. Diagnostic and test methods for detecting levels of IL-2 expression / activity, as well as compositions constituting diagnostic or test kits, are further described. JPEG2026513223000025.jpg3642
Need to check novelty before this filing date? Find Prior Art